Neurological disorders such as Alzheimer's disease, stroke, and brain cancers are difficult to
treat with current drugs as their delivery efficacy to the brain is severely hampered by the …

Translation of novel therapies for brain cancer into clinical practice is of the utmost
importance as primary brain tumors are responsible for more than 200,000 deaths …

Human neuroscience has made remarkable progress in understanding basic aspects of
functional organization; it is a renowned fact that the blood–brain barrier (BBB) impedes the …

Artificial, de-novo manufactured materials (with controlled nano-sized characteristics) have
been progressively used by neuroscientists during the last several decades. The …

Nanocarriers (synthetic/cell-based have attracted enormous interest for various therapeutic
indications, including neurodegenerative disorders. A broader understanding of the impact …

Dendrimers are polymers with well‐defined 3D branched structures that are vastly utilized in
various neurotheranostics and biomedical applications, particularly as nanocarrier vectors …

Alzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by
progressive cognitive and memory loss. The vicious circle between dysfunctional microglia …

Drug delivery to the central nervous system is restricted by the blood-brain barrier (BBB).
However, with the onset of stroke, the BBB becomes leaky, providing a window of …

The self-assembly of low-molecular-weight building motifs into supramolecular polymers
has unlocked a new realm of materials with distinct properties and tremendous potential for …

Introduction A major challenge in treating central nervous system (CNS) disorders is to
achieve adequate drug delivery across the blood–brain barrier (BBB). Receptor-mediated …